Drug Trial Radar · NCT04663347
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
543
Actual
Start
Nov 3, 2020
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Dec 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each participant depends upon which arm of treatment they are assigned to. * The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.
Conditions
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug
6 cycles (21-day cycles)
rituximab and lenalidomideDrug
rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
rituximab and bendamustineDrug
6 cycles (28-day cycles)
rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatinDrug
3 cycles (21-day cycles)
gemcitabine and oxaliplatinDrug
4 cycles (28-day cycles)
EpcoritamabBiological
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisoneDrug
6 cycles (21-day cycles)
LenalidomideDrug
12 cycles (28-day cycles)
rituximab, ifosfamide, carboplatin, and etoposide phosphateDrug
3 cycles (21-day cycles)
EpcoritamabBiological
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
EpcoritamabBiological
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
EpcoritamabBiological
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
EpcoritamabBiological
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
EpcoritamabBiological
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
EpcoritamabBiological
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
EpcoritamabBiological
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Rituximab and LenalidomideDrug
Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
EpcoritamabBiological
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose limiting Toxicities (DLTs)Time frame: During the first cycle (Cycle length= 28 days) in each cohort
- Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
- Part 2 (Except Arm 7): Overall Response Rate (ORR)Time frame: Up to 3 years
Locations
57 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Cedars-Sinai Medical Center
Los Angeles, California
David Geffen School of Medicine at UCLA
Los Angeles, California
University of California San Francisco
San Francisco, California
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai
New York, New York
Memorial Sloan Kettering CC
New York, New York
Levine Cancer Center
Charlotte, North Carolina
Southwestern Medical Center
Dallas, Texas
Austin Health
Heidelberg, Australia
Linear Clinical Research Limited
Nedlands, Australia
AZ Sint-Jan
Bruges, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
CHU UCL Namur Site Godinne
Yvoir, Belgium
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni nemocnice Ostrava
Ostrava - Poruba, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Vseobecna Fakultni Nemocnice
Prague, Czechia
Århus Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Vejle Sygehus
Vejle, Denmark
Kuopio University Hospital
Kuopio, Finland
HUS Cancer Center
Lahti, Finland
Hopital Claude Huriez - CHRU Lille
Lille, France
Hôpital de la Timone
Marseille, France
Hôpital Saint-Louis
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Italy
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy
Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS
Candiolo, Italy
IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST
Meldola, Italy
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
Reggio Emilia, Italy
Amsterdam UMC, Locatie VUMC
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen (UMCG)
Groningen, Netherlands
Leids Universitair Medisch Centrum
Leiden, Netherlands
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.